Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.
He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.
Latest From Andrew McConaghie
TIGIT is not the only novel IO mechanism showing promise, with market leaders Merck and BMS showcasing data from other early stage combinations with Opdivo and Keytruda, while Servier presented a possible three-way combo.
Keytruda-Lenvima picked out as pick of combination therapies from the European cancer congress.
Roche is hoping the investigational oral drug can help it expand its presence in breast cancer and break into the prostate cancer market – but the signals are decidedly mixed.
Analysts agree that new Phase III data suggests the antibody-drug conjugate will be a new standard of care in third-line TNBC, with potential in earlier treatment lines and in several other tumor types.
A composite endpoint conceals Actemra’s lack of mortality benefit – while life-saving dexamethasone gets EMA endorsement.
The world is waiting for Moderna’s COVID-19 vaccine results, but meanwhile the company is exploring new avenues to secure long-term growth